Compare Atlassian Corporation PLC (TEAM) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Atlassian Corporation PLC vs 10X Genomics Inc — how do they compare? Atlassian Corporation PLC trades at $204 (market cap $49.56B), while 10X Genomics Inc trades at $79.4 (market cap $9.92B). The key difference: Atlassian Corporation PLC is far larger — about 5× 10X Genomics Inc's market cap, and Atlassian Corporation PLC is trading nearer its 52-week high, 10X Genomics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Atlassian Corporation PLC for 64 Days and 10X Genomics Inc for 92 Days on average.
| TEAM | TXG | |
|---|---|---|
Market Cap | $49.56B | $9.92B |
Volume | 1,747,462 | 9,372,166 |
Sector | Technology | Health |
52-Week High | $203.57 | $97.74 |
52-Week Low | $57.15 | $11.48 |
Typical Hold Time | 64 Days | 92 Days |
Enterprise Value | $49.56B | $9.44B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Atlassian (TEAM) trades at $203.57, up 4.94% with strong technical momentum and bullish moving averages. The stock shows improving fundamentals with revenue growth from $5.22B in 2025 to projected $6.6B in 2026, though it remains unprofitable with a -0.82% net margin. Recent earnings beats and accelerating cloud/AI adoption drive positive sentiment, with analyst consensus strongly bullish at 70% buy ratings.
Outlook remains positive due to cloud migration progress and AI product adoption, but investors face valuation concerns with elevated P/S of 7.75 and EV/EBITDA of 233.57. Key risks include persistent profitability challenges and competitive pressures in enterprise software. Current price exceeds consensus target of $191.16, suggesting near-term consolidation potential.
10x Genomics (TXG) trades at $77.28, down 4.19% on the day, amid a bearish technical signal. The company reported revenue of $642.82M in 2025, with a net loss of $43.54M, though it has beaten EPS estimates for three consecutive quarters. Recent news highlights the launch of its Atera spatial biology platform and a patent victory, signaling innovation and market strength. Cash flow from operations improved to $136.05M in 2025, indicating better operational efficiency.
The outlook is cautiously optimistic, with strong product demand and improving margins offering upside potential. However, persistent losses, high valuation multiples, and competitive pressures present significant risks. Analyst consensus is mixed, with a $74.30 price target slightly below the current price, reflecting uncertainty about near-term profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Atlassian Corporation PLC
Atlassian produces software that helps teams work together more efficiently and effectively. The company provides project planning and management software, collaboration tools, and IT help desk solutions. The company operates in four segments: subscriptions (term licenses and cloud agreements), maintenance (annual maintenance contracts that provide support and periodic updates and are generally attached to perpetual license sales), perpetual license (upfront sale for indefinite usage of the software), and other (training, strategic consulting, and revenue from the Atlassian Marketplace app store). Atlassian was founded in 2002 and is headquartered in Sydney.
Read more on TEAM →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
